Abstract

Ocriplasmin is an enzymatic drug used intravitreally to lyse focal vitreomacular adhesion and traction.We present a 45-year-old Bahraini female who developed a neurosensory macular retinal detachmentfrom subfoveal fuid collection four weeks after its successful release following an ocriplasminintravitreal injection. Subfoveal fuid is a well-known side effect of intravitreal ocriplasmin, mostlyresolving spontaneously and completely over a period of few months. In order to reduce the attendantvisual disability, rather than waiting for its natural recovery, we chose to treat it with oral carbonicanhydrase inhibitor, acetazolamide with an encouraging outcome. This drug is known to help inresorption of subfoveal fuid in the condition of central serous chorioretinopathy. However, to thebest of our knowledge, its role is not explored in post-ocriplasmin setting. The purpose of this casepresentation is to highlight the possible benefcial role of carbonic anhydrase inhibitors in ocriplasmin-related subfoveal neurosensory detachment.

Keywords: Neurosensory retinal detachment, Subfoveal fuid, Ocriplasmin, Vitreomacular adhesion,Vitreomacular traction, Carbonic anhydrase inhibitor